Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
- PMID: 19116963
- DOI: 10.1002/art.24232
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
Abstract
Objective: Antiphospholipid antibodies (aPL), namely anticardiolipin antibodies (aCL) and lupus anticoagulant (LAC), have been associated with an increased risk of thrombosis in systemic lupus erythematosus (SLE). We examined additional thrombosis risk factors (aPL profile, SLE-related, and traditional risk factors) and the primary thrombosis prevention in SLE patients with and without aPL.
Methods: All SLE patients with positive aPL but without previous thrombotic manifestations who were regularly followed up at our department (n = 144) and 144 age- and sex-matched SLE patients with negative aPL were included in this study. The median followup times were 104 and 112 months, respectively. The demographic, clinical, laboratory, and treatment characteristics and the traditional thrombosis risk factors were recorded.
Results: The thrombosis rate was 29 per 144 aPL-positive patients (20.1%) and 11 per 144 aPL-negative patients (7.6%; P = 0.003). In multiadjusted analysis, significant predictors of thrombosis were male sex (hazard ratio [HR] 6.25, P < 0.01), LAC (HR 3.48, P = 0.04), and constantly positive aCL (HR 5.87, P = 0.01) for aPL-positive patients, while male sex (HR 7.14, P = 0.03) and hypertension were predictors for aPL-negative patients (HR 6.49, P = 0.03). Additionally, the duration of low-dose aspirin treatment played a protective role against thrombosis in aPL-positive patients (HR per month 0.98, P = 0.05), as did the duration of hydroxychloroquine in both aPL-positive (HR per month 0.99, P = 0.05) and aPL-negative patients (HR per month 0.98, P = 0.04).
Conclusion: Independent predictors of thrombosis for aPL-positive patients were male sex, LAC, and constantly positive aCL, and for aPL-negative patients were male sex and hypertension. The duration of low-dose aspirin use played a protective role against thrombosis in aPL-positive patients as did the duration of hydroxychloroquine in both groups.
Similar articles
-
Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.Lupus. 2007;16(10):810-6. doi: 10.1177/0961203307083316. Lupus. 2007. PMID: 17895304
-
Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.Thromb Haemost. 1996 Dec;76(6):916-24. Thromb Haemost. 1996. PMID: 8972011
-
Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.Arthritis Rheum. 2004 Aug;50(8):2569-79. doi: 10.1002/art.20433. Arthritis Rheum. 2004. PMID: 15334471
-
Thrombosis in systemic lupus erythematosus: risk and protection.Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1541-9. doi: 10.1586/erc.09.137. Expert Rev Cardiovasc Ther. 2009. PMID: 19954316 Review.
-
[Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].Minerva Med. 2003 Apr;94(2):63-70. Minerva Med. 2003. PMID: 12858154 Review. Italian.
Cited by
-
Hydroxychloroquine in obstetrics: potential implications of the prophylactic use of hydroxychloroquine for placental insufficiency during pregnancy.Obstet Gynecol Sci. 2024 Mar;67(2):143-152. doi: 10.5468/ogs.23252. Epub 2024 Jan 19. Obstet Gynecol Sci. 2024. PMID: 38246692 Free PMC article.
-
A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations.Cureus. 2023 Aug 18;15(8):e43725. doi: 10.7759/cureus.43725. eCollection 2023 Aug. Cureus. 2023. PMID: 37727166 Free PMC article. Review.
-
The ABCs of antiphospholipid syndrome.Arch Rheumatol. 2023 Jun 5;38(2):163-173. doi: 10.46497/ArchRheumatol.2023.41875. eCollection 2023 Jun. Arch Rheumatol. 2023. PMID: 37680521 Free PMC article. Review.
-
An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus.Biomolecules. 2023 Mar 30;13(4):617. doi: 10.3390/biom13040617. Biomolecules. 2023. PMID: 37189365 Free PMC article. Review.
-
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.Lupus Sci Med. 2023 Mar;10(1):e000864. doi: 10.1136/lupus-2022-000864. Lupus Sci Med. 2023. PMID: 36868585 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical